Possible coronavirus antiviral treatment developed by UNC Chapel Hill scientists heads to clinical trials

April 8, 2020 / By Madeline Farber | Fox News

In the rush to find a viable treatment option for COVID-19 patients, scientists at the University of North Carolina at Chapel Hill hope to have found at least one solution.

Researchers at the university’s Gillings School of Global Public Health developed a potential antiviral treatment they claim “shows promise in reducing lung damage” in those infected with the novel virus.

The antiviral treatment, EIDD-2801, was tested in mice infected with both MERS-CoV and SARS-CoV-2, the virus that causes COVID-19. The drug was also tested on cultured human lung cells infected with SARS-CoV-2, according to a news release from UNC at Chapel Hill.


Print Friendly, PDF & Email

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button